Timothy Sullivan, MD
Payments from drug & device makers
Across 337 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$907
- Sanofi$612
- CSL Behring$449
- Takeda Pharmaceuticals U.S.A., Inc.$383
- Kaleo, Inc.$278
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,63598%
- Education$1392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,750 |
| GSK | 55 | $907 |
| Sanofi | 26 | $612 |
| CSL Behring | 21 | $449 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $383 |
| Kaleo, Inc. | 15 | $278 |
| Amgen(2 entities) | 13 | $264 |
| Grifols USA, LLC | 13 | $251 |
| Novartis | 13 | $236 |
| Regeneron Healthcare Solutions, Inc. | 11 | $221 |
| Pharming Healthcare, Inc. | 6 | $204 |
| Optinose US, Inc. | 11 | $203 |
| Teva Pharmaceuticals USA, Inc. | 10 | $167 |
| Genentech USA, Inc. | 8 | $113 |
| Biocryst US Sales Co., LLC | 4 | $112 |
| Xoran Technologies LLC | 2 | $105 |
| Octapharma USA, Inc. | 5 | $85 |
| Pfizer | 4 | $73 |
| Shire North American Group Inc | 4 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Cycle Pharmaceuticals Inc | 2 | $52 |
| Boehringer Ingelheim | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$122
- RUCONEST$119
- AIRSUPRA$115
- DUPIXENT$109
How this compares
Too few allergy providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $54,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $53,479 |
| XolairOmalizumab | 13 | $50,274 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $49,570 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $32,153 |
| Spiriva RespimatTiotropium Bromide | 28 | $18,629 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $11,895 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $11,350 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $8,763 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $7,794 |
| Epinephrine | 18 | $3,939 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,221 |
| Montelukast Sodium | 252 | $3,009 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $2,663 |
| Ipratropium Bromide | 27 | $1,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $907 | $86,637126 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,750 | $65,37495 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $383 | $49,57019 claims |
| Boehringer IngelheimSpiriva Respimat | $46 | $18,62928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Utahon file to place this against a meaningful peer group, so we don't.
Other allergy in Ogden
- Vicki LyonsOgden$3K
- Douglas JonesLayton$1.4M
- Jan Bernhisel-BroadbentMurray$190K
- Jordan PittFarmington$6K
- Robert SilgeSalt Lake City$521
- Scott DicksonLogan$73
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.